Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Activation of Nrf2 and Hypoxic Adaptive Response Contribute to Neuroprotection Elicited by Phenylhydroxamic Acid Selective HDAC6 Inhibitors.

Gaisina IN, Lee SH, Kaidery NA, Ben Aissa M, Ahuja M, Smirnova NN, Wakade S, Gaisin A, Bourassa MW, Ratan RR, Nikulin SV, Poloznikov AA, Thomas B, Thatcher GRJ, Gazaryan IG.

ACS Chem Neurosci. 2018 May 16;9(5):894-900. doi: 10.1021/acschemneuro.7b00435. Epub 2018 Jan 17.

PMID:
29338172
2.

L-ascorbic acid: A true substrate for HIF prolyl hydroxylase?

Osipyants AI, Poloznikov AA, Smirnova NA, Hushpulian DM, Khristichenko AY, Chubar TA, Zakhariants AA, Ahuja M, Gaisina IN, Thomas B, Brown AM, Gazaryan IG, Tishkov VI.

Biochimie. 2018 Apr;147:46-54. doi: 10.1016/j.biochi.2017.12.011. Epub 2017 Dec 28.

PMID:
29289682
3.

Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.

Ben Aissa M, Tipton AF, Bertels Z, Gandhi R, Moye LS, Novack M, Bennett BM, Wang Y, Litosh V, Lee SH, Gaisina IN, Thatcher GR, Pradhan AA.

Cephalalgia. 2017 Jan 1:333102417737778. doi: 10.1177/0333102417737778. [Epub ahead of print]

4.

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.

Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP.

Transl Oncol. 2017 Aug;10(4):669-678. doi: 10.1016/j.tranon.2017.06.003. Epub 2017 Jun 30.

5.

Bioactive Flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers - Implications for Parkinson's Disease.

Smirnova NA, Kaidery NA, Hushpulian DM, Rakhman II, Poloznikov AA, Tishkov VI, Karuppagounder SS, Gaisina IN, Pekcec A, Leyen KV, Kazakov SV, Yang L, Thomas B, Ratan RR, Gazaryan IG.

Aging Dis. 2016 Dec 1;7(6):745-762. doi: 10.14336/AD.2016.0505. eCollection 2016 Dec.

6.

Structure-activity relationship for branched oxyquinoline HIF activators: Effect of modifications to phenylacetamide "tail".

Poloznikov AA, Zakhariants AA, Nikulin SV, Smirnova NA, Hushpulian DM, Gaisina IN, Tonevitsky AG, Tishkov VI, Gazaryan IG.

Biochimie. 2017 Feb;133:74-79. doi: 10.1016/j.biochi.2016.12.004. Epub 2016 Dec 19.

PMID:
28007502
7.

GSK-3 inhibition overcomes chemoresistance in human breast cancer.

Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP.

Cancer Lett. 2016 Oct 1;380(2):384-92. doi: 10.1016/j.canlet.2016.07.006. Epub 2016 Jul 14.

8.

Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.

Ahuja M, Ammal Kaidery N, Yang L, Calingasan N, Smirnova N, Gaisin A, Gaisina IN, Gazaryan I, Hushpulian DM, Kaddour-Djebbar I, Bollag WB, Morgan JC, Ratan RR, Starkov AA, Beal MF, Thomas B.

J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016.

9.

GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression.

Baumgart S, Chen NM, Zhang JS, Billadeau DD, Gaisina IN, Kozikowski AP, Singh SK, Fink D, Ströbel P, Klindt C, Zhang L, Bamlet WR, Koenig A, Hessmann E, Gress TM, Ellenrieder V, Neesse A.

Mol Cancer Ther. 2016 Mar;15(3):491-502. doi: 10.1158/1535-7163.MCT-15-0309. Epub 2016 Jan 28.

10.

Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.

Gaisina IN, Tueckmantel W, Ugolkov A, Shen S, Hoffen J, Dubrovskyi O, Mazar A, Schoon RA, Billadeau D, Kozikowski AP.

ChemMedChem. 2016 Jan 5;11(1):81-92. doi: 10.1002/cmdc.201500456. Epub 2015 Nov 23.

11.

Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.

Pal K, Cao Y, Gaisina IN, Bhattacharya S, Dutta SK, Wang E, Gunosewoyo H, Kozikowski AP, Billadeau DD, Mukhopadhyay D.

Mol Cancer Ther. 2014 Feb;13(2):285-96. doi: 10.1158/1535-7163.MCT-13-0681. Epub 2013 Dec 10.

12.

Characterization of maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitors as stimulators of steroidogenesis.

Gunosewoyo H, Midzak A, Gaisina IN, Sabath EV, Fedolak A, Hanania T, Brunner D, Papadopoulos V, Kozikowski AP.

J Med Chem. 2013 Jun 27;56(12):5115-29. doi: 10.1021/jm400511s. Epub 2013 Jun 17.

13.

Catalytic mechanism and substrate specificity of HIF prolyl hydroxylases.

Smirnova NA, Hushpulian DM, Speer RE, Gaisina IN, Ratan RR, Gazaryan IG.

Biochemistry (Mosc). 2012 Oct;77(10):1108-19. doi: 10.1134/S0006297912100033. Review.

14.
15.

Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth.

Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F, Burdette JE.

Anticancer Drugs. 2011 Nov;22(10):978-85. doi: 10.1097/CAD.0b013e32834ac8fc.

16.

Structure-guided design of a highly selective glycogen synthase kinase-3β inhibitor: a superior neuroprotective pyrazolone showing antimania effects.

Chen W, Gaisina IN, Gunosewoyo H, Malekiani SA, Hanania T, Kozikowski AP.

ChemMedChem. 2011 Sep 5;6(9):1587-92. doi: 10.1002/cmdc.201100231. Epub 2011 Jul 12. No abstract available.

17.

Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.

Kozikowski AP, Gunosewoyo H, Guo S, Gaisina IN, Walter RL, Ketcherside A, McClung CA, Mesecar AD, Caldarone B.

ChemMedChem. 2011 Sep 5;6(9):1593-602. doi: 10.1002/cmdc.201100188. Epub 2011 Jul 5.

18.

Glycogen synthase kinase-3β is a functional modulator of serotonin-1B receptors.

Chen L, Zhou W, Chen PC, Gaisina I, Yang S, Li X.

Mol Pharmacol. 2011 Jun;79(6):974-86. doi: 10.1124/mol.111.071092. Epub 2011 Mar 3.

19.

Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation.

Smirnova NA, Rakhman I, Moroz N, Basso M, Payappilly J, Kazakov S, Hernandez-Guzman F, Gaisina IN, Kozikowski AP, Ratan RR, Gazaryan IG.

Chem Biol. 2010 Apr 23;17(4):380-91. doi: 10.1016/j.chembiol.2010.03.008.

20.

Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.

Kim KH, Gaisina I, Gallier F, Holzle D, Blond SY, Mesecar A, Kozikowski AP.

J Mol Model. 2009 Dec;15(12):1463-79. doi: 10.1007/s00894-009-0498-x. Epub 2009 May 14.

21.

From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.

Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD, Kozikowski AP.

J Med Chem. 2009 Apr 9;52(7):1853-63. doi: 10.1021/jm801317h.

22.

The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST.

J Neurosci Res. 2009 Feb;87(2):440-51. doi: 10.1002/jnr.21850.

23.

Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.

Kozikowski AP, Gaisina IN, Yuan H, Petukhov PA, Blond SY, Fedolak A, Caldarone B, McGonigle P.

J Am Chem Soc. 2007 Jul 4;129(26):8328-32. Epub 2007 Jun 7.

PMID:
17552518
24.

Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease.

Kozikowski AP, Gaisina IN, Petukhov PA, Sridhar J, King LT, Blond SY, Duka T, Rusnak M, Sidhu A.

ChemMedChem. 2006 Feb;1(2):256-66.

PMID:
16892358

Supplemental Content

Loading ...
Support Center